神经药理学报2024，Vol.14Issue(6)：58-64,7.DOI:10.3969/j.issn.2095-1396.2024.06.009
口服化疗药希罗达应用进展
Progress in the Use of Oral Chemotherapeutic Agent Xeloda
贾晓坤1
作者信息
- 1. 张家口市中心血站体采科,张家口,075000,中国
- 折叠
摘要
Abstract
Xeloda,also known as capecitabine tablets,is the first oral fluorouracil chemotherapy drug,which is converted into 5-fluorouracil(5-FU)by intestinal absorption,and 5-FU is converted into deoxyuridylate monophosphate(FdUMP)and 5-fluoruridylate triphosphate(FUTP)by cell metabolism.It can well simulate the state of 5-FU intravenous therapy,with high effectiveness.Convenience and high efficiency are often used in adjuvant therapy,combined with paclitaxel and other drugs to treat breast cancer,gastric cancer and other diseases,but there are still many adverse reactions.This article reviews the structure,function,clinical application and clinical effect of oral chemotherapy Xeloda.关键词
希罗达/药理作用/药物代谢动力学/临床应用Key words
Xeloda/capecitabine/pharmacological effects/pharmacokinetics/clinical application分类
医药卫生引用本文复制引用
贾晓坤..口服化疗药希罗达应用进展[J].神经药理学报,2024,14(6):58-64,7.
